REAL

Financing and Reimbursement Models for Personalised Medicine: A Systematic Review to Identify Current Models and Future Options

Koleva-Kolarova, Rositsa and Buchanan, James and Vellekoop, Heleen and Huygens, Simone and Versteegh, Matthijs and Szilberhorn, László and Zelei, Tamás and Nagy, Balázs (2022) Financing and Reimbursement Models for Personalised Medicine: A Systematic Review to Identify Current Models and Future Options. APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 20. pp. 501-524. ISSN 1175-5652

[img]
Preview
Text
Kolerova_et_al_2021.pdf
Available under License Creative Commons Attribution Non-commercial.

Download (1MB) | Preview

Abstract

Background The number of healthcare interventions described as 'personalised medicine' (PM) is increasing rapidly. As healthcare systems struggle to decide whether to fund PM innovations, it is unclear what models for financing and reimbursement are appropriate to apply in this context. Objective To review financing and reimbursement models for PM, summarise their key characteristics, and describe whether they can influence the development and uptake of PM. Methods A literature review was conducted in Medline, Embase, Web of Science, and Econlit to identify studies published in English between 2009 and 2021, and reviews published before 2009. Grey literature was identified through Google Scholar, Google and subject-specific webpages. Articles that described financing and reimbursement of PM, and financing of non-PM were included. Data were extracted and synthesised narratively to report on the models, as well as facilitators, incentives, barriers and disincentives that could influence PM development and uptake. Results One hundred and fifty-three papers were included. Research and development of PM was financed through both public and private sources and reimbursed largely through traditional models such as single fees, Diagnosis-Related Groups, and bundled payments. Financial-based reimbursement, including rebates and price-volume agreements, was mainly applied to targeted therapies. Performance-based reimbursement was identified mainly for gene and targeted therapies, and some companion diagnostics. Gene therapy manufacturers offered outcome-based rebates for treatment failure for interventions including Luxturna(R), Kymriah(R), Yescarta(R), Zynteglo((R),) Zolgensma(R) and Strimvelis(R), and coverage with evidence development for Kymriah(R) and Yescarta(R). Targeted testing with OncotypeDX(R) was granted value-based reimbursement through initial coverage with evidence development. The main barriers and disincentives to PM financing and reimbursement were the lack of strong links between stakeholders and the lack of demonstrable benefit and value of PM. Conclusions Public-private financing agreements and performance-based reimbursement models could help facilitate the development and uptake of PM interventions with proven clinical benefit.

Item Type: Article
Subjects: H Social Sciences / társadalomtudományok > HG Finance / pénzügy
R Medicine / orvostudomány > R1 Medicine (General) / orvostudomány általában
SWORD Depositor: MTMT SWORD
Depositing User: MTMT SWORD
Date Deposited: 29 Sep 2022 08:42
Last Modified: 29 Sep 2022 08:42
URI: http://real.mtak.hu/id/eprint/150562

Actions (login required)

Edit Item Edit Item